---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-339147"
form_type: "8-K"
ticker: "NERV"
cik: "0001598646"
company_name: "Minerva Neurosciences, Inc."
filed_at: "2026-08-07T11:13:34+00:00"
generated_at: "2026-08-07T11:15:19.790511+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Minerva Q2 GAAP net income $17.5M on $27.6M non-cash warrant gain; adjusted loss $7.8M

## Summary
- Q2 2026 GAAP net income of $17.5M ($0.36 basic, $(0.14) diluted) vs net loss of $3.3M year-ago; driven by $27.6M non-cash warrant gain.
- Adjusted non-GAAP net loss of $7.8M vs $3.0M year-ago; H1 adjusted loss $15.1M vs $6.4M. Cash $75.4M, down from $82.4M at Dec 31, 2025.
- R&D expense $7.2M (Q2) vs $1.3M; G&A $3.5M vs $2.1M, up on C19 trial costs, professional fees and compensation.
- Phase 3 C19 roluperidone trial (380 patients, ~40 sites) on track; Phase A topline expected 2H 2027, Phase B 2H 2028.
- Scientific Advisory Board expanded to 11 members, adding Correll, Leucht and Sand.

## SEC filing metadata
- accession: 0001193125-26-339147
- form_type: 8-K
- ticker: NERV
- cik: 0001598646
- company_name: Minerva Neurosciences, Inc.
- filed_at: 2026-08-07T11:13:34+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/0001193125-26-339147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/d22348d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-339147
- JSON: https://secwatch.observer/filing/0001193125-26-339147.json
- Plain text: https://secwatch.observer/filing/0001193125-26-339147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.